title: Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.
abstract: There is ample evidence for intra-patient evolution of the human immunodeficiency virus type 1 (HIV-1) biological phenotype during the pathogenic process. Evolution often involves switch of coreceptor use from CCR5 to CXCR4, but change to more flexible use of CCR5 occurs over time even in patients with maintained CCR5 use. The increasing use of entry inhibitors in the clinic, often specific for one or the other HIV-1 coreceptor or with different binding properties to CCR5, calls for virus testing in patients prior to treatment initiation. Cell lines expressing CCR5/CXCR4 chimeric receptors are tools for testing viruses for mode of CCR5 use. It is conceivable that small-molecule entry inhibitors that differentially bind to CCR5 can be matched for best effect against HIV-1 with different modes of CCR5 use, thereby allowing an individualized drug choice specifically tailored for each patient.
authors.affiliation: Department of Laboratory Medicine, Division of Medical Microbiology, Lund, Sweden. eva_maria.fenyo@med.lu.se
authors.forename: E M
authors.initials: EM
authors.lastname: Fenyö
authors.forename: J
authors.initials: J
authors.lastname: Esbjörnsson
authors.forename: P
authors.initials: P
authors.lastname: Medstrand
authors.forename: M
authors.initials: M
authors.lastname: Jansson
mesh_terms: D002460:Cell Line; D015195:Drug Design; D006031:Glycosylation; D015658:HIV Infections / Q000378:metabolism*; D015497:HIV-1 / Q000378:metabolism*; D054884:Host-Pathogen Interactions; D006801:Humans; D019713:Receptors, CCR5 / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000378:metabolism*
chemical_list: D019713:Receptors, CCR5; D019718:Receptors, CXCR4